Blue Jet Healthcare Ltd. IPO
IPO Timeline
Category-wise Subscription
| Category | Sub (x) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 12,142,580 (50%) | — | ₹42,013 Cr |
| NII (HNI) | — | 3,642,774 (15%) | — | ₹12,604 Cr |
| Retail | — | 8,499,806 (35%) | — | ₹29,409 Cr |
| Σ Total | — | 24,285,160 (100%) | — | ₹840,267 Cr |
Only available investor categories are shown. Amount is auto-calculated when shares offered and issue price are available.
Issue Details
Minimum Investment (Lot-wise)
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 43 | ₹14,878 |
| Retail (Max) | 13 | 559 | ₹193,414 |
| S-HNI (Min) | 14 | 602 | ₹208,292 |
| B-HNI (Min) | 67 | 2,881 | ₹996,826 |
Financial Statements Amount in Crore
| Metric | 30 Jun 2023 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|
| Revenue | 185 | 745 | 703 |
| Profit After Tax | 44 | 160 | 182 |
| Net Worth | 726 | 681 | 522 |
| Total Assets | 904 | 862 | 713 |
| Reserves & Surplus | 691 | 647 | 487 |
Valuation & Key Ratios
Grey Market Premium (GMP)
GMP is an unofficial grey market indicator and does not guarantee actual listing price. Invest at your own risk.
Objects of the Issue
- The company will not receive any proceeds from the Offer and all the Offer Proceeds will be received by the Selling Shareholders, in proportion to the Offered Shares sold by the respective Selling Shareholders as part of the Offer. –
Company Overview
Incorporated in 1968, Blue Jet Healthcare is a pharmaceutical and healthcare ingredient and an intermediate company. Blue Jet Healthcare was the first manufacturer of saccharin and its salts (artificial sweeteners) in India. They later expanded into contrast media intermediates, which are used in CT scans and MRIs. The company mainly deals in three product categories: (i) contrast media intermediates, (ii) high-intensity sweeteners, and (iii) pharma intermediates and active pharmaceutical ingredients.
Blue Jet Healthcare is a global, science-led pharmaceutical company. They are the provider of:
- Process development and production capabilities
- Global regulatory support
- Collaboration, development, and manufacturing of advanced pharmaceutical intermediates and API.
The company has three manufacturing facilities, which are situated in Shahad (Unit I), Ambernath (Unit II) and Mahad (Unit III) in the state of Maharashtra, India, with an annual installed capacity of 200.60 KL, 607.30 KL and 213.00 KL, respectively, as of June 30, 2023.
Company's core strength lies in the following
- Huge manufacturing capacity of contrast media intermediates in India.
- The company operates in a niche market that has high entry barriers.
- Long-term relationships and long term contracts with multi-national customers.